We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Jie D’Elia is the Executive Director, Business Development Transactions at Bristol-Myers Squibb. In this role, Jie serves as the global lead in negotiating business development and licensing transactions.
Prior to joining Bristol-Myers Squibb in 2013, Jie served as the Corporate Vice President and Global Head of Business Development at Simcere Pharmaceutical, a fast growing leading Chinese pharmaceutical company with presence in North America and Europe. While at Simcere, she led the conceptualization and negotiation of a series of first-in-kind, high impact strategic partnerships, including a joint venture between Simcere and Merck Sharp & Dohme. Prior to joining Simcere, Jie worked at AstraZeneca and the Boston Consulting Group.
Jie holds a Ph.D. in Pharmacy from the University of Texas at Austin and an M.B.A from Columbia Business School.
This speaker's sessions: